Dr. Reddy's Laboratories Ltd Q1FY22 consolidated PAT at Rs. 380.4 Cr

The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.

Dr. Reddy's Laboratories launches Doxycycline Capsules, 40 mg in US

ORACEA is a trademark of Galderma Holdings, S.A.

Dr. Reddy's and Nestle India to form JV for health science nutraceutical portfolio

The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios

Dr. Reddy's launches drug-free migraine management device Nerivio in Europe

Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India

Vericiguat works on a pathway not currently targeted by existing heart failure treatments

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U

Dr. Reddy's Laboratories launches Versavo in the UK

Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK

Dr. Reddy's becomes first Indian pharma company to debut on the DJSI

Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis

Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug

Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya

Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India

Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain